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vAbstract.
 Py-Im polyamides are cell-permeable, programmable, sequence-specific, DNA 
minor groove-binding small molecules.  When designed to bind a DNA sequence that 
matches the consensus DNA-binding sequence of a transcription factor, they can be used 
to block the binding of that transcription factor to its response element in vitro and in cell 
culture.  We have used this approach to inhibit the genotropic activity of the endogenous 
transcription factors HIF1α, glucocorticoid receptor (GR), and androgen receptor (AR). 
In this work, we report the completion of a library of hairpin Py-Im polyamides targeted 
to all possible 5’-WGNNNW-3’ (W = A or T) sequences.  These compounds bind their 
target DNA sequences with high affinity.  One compound from this set targets the sequence 
5’-WGWWCW-3’, which matches the DNA binding consensus sequence of GR and 
AR and has been shown to inhibit the gene regulatory activity of these proteins in cell 
culture.  Herein, we show that a cyclic derivative of this compound maintains its activity 
against AR-driven gene expression in hormone-sensitive LNCaP prostate cancer cells.  As 
androgen receptor signaling is crucial to prostate cancer growth and metastasis even in its 
recurrent form, we next examine the activity of the AR/GR antagonist in a tissue culture 
model of castration-resistant prostate cancer.  In this model, the polyamide retains its 
activity against AR-driven mRNA expression, but it fails to inhibit the binding of AR to its 
response element.  The polyamide-mediated repression is also accompanied by significant 
cell stress and cytotoxicity, which are explored in the final two chapters of this thesis.  The 
former investigates a role for polyamides as inhibitors of DNA Topoisomerase II.  Despite 
in vitro evidence indicating polyamides prevent Topoisomerase II binding, no evidence for 
this is found in cell culture.  The final chapter reveals that polyamide-mediated cytotoxicity 
is likely due to inhibition of DNA synthesis.  This occurs at concentrations similar to those 
used for transcription factor inhibition, suggesting that S-phase disturbance accompanies 
efforts to regulate gene expression with polyamides.
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